Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development
"....One way to accomplish this is to emphasize phase IV postmarketing,
hypothesis-driven
clinical trials with biological characterization
that would permit an accurate definition of the association of
low-prevalence
gene alterations with toxicity or response in large
cohorts."
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.